# AF-HPA and auristatin F

Source: https://onco.cc/terms/af-hpa/  
OnCo record `af-hpa` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AF-HPA is an auristatin cargo used in the Dolaflexin platform. It can convert to active auristatin F, which has less access across membranes.

## Summary

The Dolaflexin preclinical studies distinguish membrane-accessible auristatin F-hydroxypropylamide, or AF-HPA, from its less membrane-accessible but still active auristatin F metabolite. Auristatin F is not the same chemical as monomethyl auristatin F.

The XMT-1536 preclinical report describes roughly 10 to 15 AF-HPA molecules per antibody. This is a preparation-specific report, rather than a fixed mean or a common loading of eight. The earlier polyacetal Fleximer study used a vinca derivative; its platform name must not be treated as evidence for Dolaflexin composition. Cell and animal activity does not establish patient benefit or complete payload confinement.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: AF-HPA; auristatin F-hydroxypropylamide; Auristatin F-hydroxypropylamide

### Scoped source observations

```json
{
  "chemicalObservations": [
    {
      "sources": [
        {
          "label": "Dolaflexin: AF-HPA and auristatin F in preclinical models (2021)",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33722857/"
        }
      ],
      "checkedOn": "2026-11-09",
      "species": {
        "name": "AF-HPA"
      },
      "context": "Dolaflexin preclinical conjugate and metabolite studies.",
      "method": "Cell and animal characterisation.",
      "statement": "Membrane-accessible AF-HPA can convert to the less membrane-accessible but active auristatin F species.",
      "evidenceType": "experimental",
      "limitation": "Auristatin F is distinct from MMAF; the conversion does not establish complete confinement or human safety.",
      "property": "release"
    },
    {
      "sources": [
        {
          "label": "XMT-1536 preclinical composition and NaPi2b-directed models (2021)",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33722858/"
        }
      ],
      "checkedOn": "2026-11-09",
      "species": {
        "name": "AF-HPA"
      },
      "conjugate": {
        "name": "XMT-1536"
      },
      "context": "The named XMT-1536 product or preparation described by the source.",
      "method": "Composition reported for the preclinical conjugate preparation.",
      "statement": "The preclinical report describes approximately 10 to 15 AF-HPA molecules per antibody; no fixed mean is inferred from that range.",
      "evidenceType": "experimental",
      "limitation": "This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.",
      "property": "conjugate-loading"
    }
  ]
}
```

## Sources

- Dolaflexin: AF-HPA and auristatin F in preclinical models (2021): https://pubmed.ncbi.nlm.nih.gov/33722857/
- XMT-1536 preclinical composition and NaPi2b-directed models (2021): https://pubmed.ncbi.nlm.nih.gov/33722858/
- Polyacetal Fleximer with a vinca derivative, a distinct platform (2015): https://pubmed.ncbi.nlm.nih.gov/26113086/

## Connected records

- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Drug efflux pumps (ABC transporters)](https://onco.cc/terms/efflux-pump/), [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Upifitamab rilsodotin](https://onco.cc/drugs/upifitamab-rilsodotin/)

---
JSON: https://onco.cc/api/v1/entities/af-hpa.json